Mary's Medicinals Announces Its Intention to Participate in the Newly Announced Medicare and Medicaid CMS Trial Program with Its Award-Winning Cannabinoid-Based Wellness Products

CMS's new BEI program allows cannabinoid products containing up to 3 mg THC per serving, and Mary's Medicinals (MM Brands) announced it will participate in the CMS Innovation Center trial via ACO REACH and EOM, with LEAD model access beginning in 2027. This regulatory inclusion materially improves potential healthcare access and reimbursement pathways for full‑spectrum hemp-derived CBD products, presenting a positive commercial and market-access catalyst for leading CBD therapy providers.

Analysis

CMS opening a reimbursement pathway for low-THC, standardized cannabinoid products materially changes go-to-market economics: it shifts the business model from retail/dispensary distribution toward clinician-driven prescribing and ACO formulary placement. Even a conservative penetration — 0.1–0.5% of ~70M Medicare/Medicaid lives — implies hundreds of thousands of recurring users, which converts high CAC retail customers into predictable, reimbursed volume and favors manufacturers with GMP-like controls and clinical data.

Second-order winners are not just product makers but the infrastructure that vets and delivers reimbursed therapies: labs for potency/contaminant testing, specialty pharmacies and PBMs that manage ACO formularies, and MA/ACO operators that can internalize savings vs. opioids. Conversely, commodity hemp suppliers and low-barrier retail brands face margin compression and distribution exclusion if they can’t meet clinical/regulatory requirements, accelerating consolidation in the supply chain.

Timing and key catalysts are concentrated: ACO / MA formulary decisions and pilot enrollment over the next 12–24 months, with measurable utilization and patient-outcome readouts 24–48 months out. Major risks that would reverse the trade are an adverse FDA stance or restrictive CMS coverage rules that cap reimbursement rates, legal challenges from state-level regulators, or safety signals that reclassify access — any of which could relegate this back to niche retail demand within 6–18 months.

Key Decisions for Investors

• Long UNH (UnitedHealth) stock — 6–12 month horizon. Rationale: preferred exposure to ACO/MA capture of any downstream savings and formulary-management upside. Risk/reward: 15–25% upside if MA plans adopt cannabinoid therapy at scale; downside ~10–12% on policy or macro shocks. Position size: modest (1–2% portfolio) to earn asymmetric systems-level benefit.
• Long LH (Labcorp) or DGX (Quest Diagnostics) — 3–9 month horizon. Rationale: increased testing/compliance demand as payers and ACOs mandate potency and contaminant verification. Trade: buy LH stock or 6–9 month call spread; upside driven by incremental lab volume, downside limited to ~15% operational risk if volume take-up lags.
• Long TLRY (Tilray Brands) — 9–18 month horizon via equity or ITM call options. Rationale: vertical players with pharma-grade manufacturing and distribution optionality should consolidate medical access wins. Risk/reward: high volatility; potential 30–50% upside if TLRY secures ACO placements, but large downside if FDA/CMS restricts coverage — cap exposure to 1–2% NAV.
• Pair trade: Long UNH / Short PFE (Pfizer) — 6–12 month horizon. Rationale: isolate ACO/MA systems-capture and specialty pharmacy gains versus incumbents reliant on high-volume branded analgesics/specialty pharma. Structure as equal dollar exposure; target capture of relative 10–20% outperformance for the long leg while keeping net market exposure low.